Last reviewed · How we verify
nifedipine controlled release tablets
nifedipine controlled release tablets is a Calcium channel blocker (dihydropyridine) Small molecule drug developed by Guangzhou First People's Hospital. It is currently FDA-approved for Hypertension, Angina pectoris. Also known as: Adalat GITS.
Nifedipine is a calcium channel blocker that reduces calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and decreased blood pressure.
Nifedipine controlled release tablets are a small molecule medication used to treat essential hypertension and hypertension. They are also studied for their potential effects on chronic kidney disease, particularly in combination with Nephropathy Formula No. 1.
At a glance
| Generic name | nifedipine controlled release tablets |
|---|---|
| Also known as | Adalat GITS |
| Sponsor | Guangzhou First People's Hospital |
| Drug class | Calcium channel blocker (dihydropyridine) |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nifedipine selectively blocks L-type calcium channels in the cell membrane, preventing calcium-dependent contraction of vascular smooth muscle. This leads to peripheral vasodilation, reduced peripheral vascular resistance, and decreased myocardial oxygen demand. The controlled-release formulation provides sustained drug delivery over 24 hours, enabling once-daily dosing with more stable blood pressure control.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Headache
- Flushing
- Peripheral edema
- Dizziness
- Palpitations
Key clinical trials
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy (PHASE4)
- Persistent Postpartum Hypertension Pilot Trial (PHASE4)
- Medicine-induced Cardiac Hemodialysis on COVID-19 (PHASE4)
- Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study
- Clinical Study on the Effect of PTH on CYP3A4 Activity
- A Study To Test The Effect Of Apatinib On P450 Enzymes (PHASE1)
- Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nifedipine controlled release tablets CI brief — competitive landscape report
- nifedipine controlled release tablets updates RSS · CI watch RSS
- Guangzhou First People's Hospital portfolio CI
Frequently asked questions about nifedipine controlled release tablets
What is nifedipine controlled release tablets?
How does nifedipine controlled release tablets work?
What is nifedipine controlled release tablets used for?
Who makes nifedipine controlled release tablets?
Is nifedipine controlled release tablets also known as anything else?
What drug class is nifedipine controlled release tablets in?
What development phase is nifedipine controlled release tablets in?
What are the side effects of nifedipine controlled release tablets?
What does nifedipine controlled release tablets target?
Related
- Drug class: All Calcium channel blocker (dihydropyridine) drugs
- Target: All drugs targeting L-type voltage-gated calcium channel
- Manufacturer: Guangzhou First People's Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Angina pectoris
- Also known as: Adalat GITS
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing